Clinical trial on effect of Bilvashalatu Majja and Apakva Bilvaphala Majja in the patient suffering from irregular bowel habits (Sometime Diarrhea or constipation).

Study on Bilvashalatu (Aegle marmelos Linn.) and assess its clinical efficacy in the management of Grahani roga wsr to IBS - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087826

Enrollment

Registered

2025-05-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K582- Mixed irritable bowel syndrome

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients having cardinal symptom of Grahani roga i.e. Muhur Baddha or Drava Mala pravritti and any two of associated complain i.e. Punahapunah Malapravritti, Bhojanottar Malapravritti, Saphena-Sashabda-Sashoola Malapravritti, Arochaka, Udarashool, Katu - Tikatamlodgara will be included for the study Patient must have more than or equal to 2 of Rome IV criteria of IBS associated with abdominal pain on average at least 1 day/week in the last 3 months will be included.

Exclusion criteria

Exclusion criteria: 1.Patients suffering from Acute diarrhea, Intestinal T.B., Ulcerative colitis, Gastric and peptic ulcer, Crohn s disease, any genetic and auto immune GIT disorders. 2.Patient suffering from Bleeding per rectum 3.Pregnant women and Lactating mother. 4.Uncontrolled systemic disorders like Hypertension (more than 160/100mm-Hg) and Diabetes mellitus (RBS more than 180mg/dl). 5.Known cases of Tuberculosis, HIV, VDRL, Hep. B positive, COPD etc. 6.Patients who have a history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.

Design outcomes

Primary

Measure	Time frame
1. Changes in scoring pattern in symptoms of Grahani roga 2. IBS - Symptom Severity Scale - on 0th, 14th, 28th day.Timepoint: 0th and 28th day	—

Secondary

Measure	Time frame
1. Agnibala assessment 2. Number of adverse events will be assessed on the basis of lab investigation. 3.Changes in Stool investigations i.e. Routine & Microscopic, Occult blood, Mucus, Indigested food particles 4.Changes in Haematological parameter i.e. CBC, ESR 5.Changes in Biochemical parameter i.e. SGPT, SGOT and Serum creatinine.Timepoint: 0th and 28th day	—

Countries

India

Contacts

Public ContactDr Sheetal Chandulal Dhamecha

Institute of Teaching and Research in Ayurveda

brpayu@gmail.com9427574590

Outcome results